Skip to main content

Carlos Molina Cateriano

Institutions of which they are part

Head of group
Stroke research
Vall Hebron Institut de Recerca

Carlos Molina Cateriano

Institutions of which they are part

Head of group
Stroke research
Vall Hebron Institut de Recerca

Projects

PROOF: Penumbral Rescue by Normobaric O=O Administration in Patients With Ischaemic Stroke and Target Mismatch ProFile: A Phase II Proof-of-Concept Trial

IP: Carlos Molina Cateriano
Collaborators: Estela Sanjuan Menendez
Funding agency: EUROPEAN COMMISSION
Funding: 171429.75
Reference: PROOF_H2020PHC2016/MOLINA
Duration: 01/01/2017 - 18/02/2022

Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) Trial

IP: Carlos Molina Cateriano
Collaborators: Marta Aurora Rubiera Del Fueyo, David Rodriguez Luna, Mª Ángeles Muchada López
Funding agency: National Health and Medical Res Council (NHMR
Funding: 1950
Reference: TASTE_HMRI2012101
Duration: 19/04/2017 - 16/04/2018

TEMPO-2: Ensayo controlado aleatorizado de TNK-tPA frente a las normas asistenciales para accidente cerebrovascular isquémico menor con oclusión demostrada.

IP: Carlos Molina Cateriano
Collaborators: -
Funding agency: University of Calgary
Funding: 45000
Reference: TEMPO2_CIHR2016
Duration: 01/09/2016 - 31/12/2025

Malalties Neurovasculars (GRC)

IP: Joan Montaner Villalonga
Collaborators: Marta Aurora Rubiera Del Fueyo, Jorge Pagola Pérez Blanca, Malalties Neurovasculars (GRC), José Alvarez Sabin, Anna Penalba Morenilla, Maria Mar Hernandez Guillamon, Malalties Neurovasculars (GRC), Marc Ribó Jacobi, Maria Pilar Delgado Martínez, Carlos Molina Cateriano, Anna Rosell Novel, David Rodriguez Luna, Mª Ángeles Muchada López, Estevo Santamarina Pérez, Manuel Quintana Luque
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 48000
Reference: 2014 SGR 686
Duration: 01/01/2014 - 31/12/2016

Related news

The Consortium will create a platform to facilitate a personalised management for stroke patients, enabling a more efficient personalized monitoring and patient follow up.

Funding is key to bringing the neuroprotective drug ApTOLL to market and providing a new therapeutic option for the patients.

The award is a recognition for his significant contribution to the development of research in multiple sclerosis within the Catalan Institute of Health.

Related professionals

Mireia Benito Jimenez

Mireia Benito Jimenez

Research assistant
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Margot Noemi Costa Gutiérrez

Margot Noemi Costa Gutiérrez

Administrative
General Services and Infrastructures Unit
Manager
Read more
Yasmine Margaret Baktash

Yasmine Margaret Baktash

Postdoctoral researcher
Infectious Diseases
Read more
Elba Agusti Rovira

Elba Agusti Rovira

Research technician
Donation and transplantation of organs, tissues and cells
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.